Happy Holidays! The prIME Oncology prIME LINES team would like to extend a sincere thank you for a wonderful 2018. We look forward to a successful 2019 with you, our valued readers. We’ll see you again January 4, 2019, with the latest news and information. Thank you for your continued interest in our blog.
Allogeneic hematopoietic cell transplantation (allo-HCT) is an important treatment for many hematologic malignancies. While this therapy can be life saving for some patients with hematologic cancers, it can be associated with a complications, including infection, organ toxicity, and graft-versus-host disease (GVHD). The composition of the intestinal microbiota is a known factor influencing toxicity and outcomes […]
Chimeric antigen receptor modified (CAR) T cells have emerged in recent years as a novel and highly effective treatment option for patients with different hematologic malignancies, including diffuse large B-cell lymphoma (DLBCL), acute lymphocytic leukemia (ALL), and chronic lymphocytic leukemia (CLL). At the 2018 American Society for Hematology (ASH) Annual Meeting, new findings from several […]
Anemia is a major morbidity associated with low- and intermediate-risk myelodysplastic syndrome (MDS), and patients with MDS often become dependent on red blood cell (RBC) transfusion to counteract symptoms of anemia. Luspatercept, a first-in-class erythroid-maturation agent, is involved in regulation of late stage RBC maturation and is currently being investigated as a treatment for patients […]
From December 1 to December 4, more than 25,000 attendees from around the world gathered in San Diego, California, to attend the 60th American Society for Hematology (ASH) Annual Meeting, where the latest developments and new findings in the hematology field were presented. Over the next several weeks, prIME Lines will highlight some of the […]
Three New Therapies for Acute Myeloid Leukemia. The United States Food and Drug Administration (FDA) granted approval for three new agents for acute myeloid leukemia (AML) in November. Gilteritinib (Xospata®, Astellas), a FLT3-targeting tyrosine kinase inhibitor (TKI), was approved for use in adults with relapsed or refractory AML who have an FLT3 mutation, as detected […]
Treatment options for patients with metastatic osteosarcoma who progress on first-line chemotherapy are limited, and prognosis for these patients is extremely poor. The activity of second-line chemotherapy in osteosarcoma is marginal, and treatment with checkpoint inhibitors, unfortunately, also appears ineffective. More promising results were reported with targeted therapy, in particular with agents targeting angiogenesis and […]